© 2025 Stocks Telegraph All rights reserved.
Most stock quote data provided by Financial Modeling Prep
Based on recent data, Lumos Pharma, Inc. (LUMO) shows an Average True Range (ATR) of 0.09 and an Enterprise Value of -5.83M. Its average trading volume over the past 3 months is N/A, indicating liquidity. These fundamental metrics provide insight into LUMO's underlying financial health and market activity.
Lumos Pharma, Inc. (LUMO) technical indicators as of December 22, 2025: the SMA 20 is 0.34%, SMA 50 at 3.61%, and SMA 200 at 40.73%. The RSI 14 value is 55.58, suggesting its current momentum. These technical analysis signals help assess LUMO's price trends and potential future movements.
Lumos Pharma, Inc. (LUMO) stock performance overview as of December 22, 2025: The 52-week high is N/A (currently -5.15% below), and the 52-week low is N/A (currently 216.77% above). Over the past year, LUMO's performance is N/A, compared to the S&P 500's 12.87% change.
According to market data, Lumos Pharma, Inc. (LUMO) stock's recent performance metrics show that over the last month, LUMO is -0.69%, with a Year-to-Date (YTD) performance of 36.48%. Over the past year, the stock has seen a N/A change. These figures summarize LUMO's price movements across various periods, reflecting its historical returns.
According to current financial data, LUMO stock's P/E (TTM) ratio is -2.41, which compares to the S&P 500's P/E of 32.59. The sector median P/E is -1.24. Key valuation ratios for LUMO, including P/S (30.92), P/B (7.35), and P/FCF (-3.30), offer insights into how the company is valued relative to its earnings, sales, book value, and free cash flow.